TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration-time curve from time 0 to 24 hours after dosing of abiraterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline HbA1c at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline HbA1c at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence rate of VVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of poor response to neoadjuvant treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who underwent TURBT without conversion to general anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decreased pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion-related acute lung injury incidence
Endpoint domain: Adverse events/effects
Primary endpoint: use of rescue antiemetics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Evaporametry changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: α-diversity of the gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of patients with biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with benefit from intra-treatment PET-CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum QSSM level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to locate axillary nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mobilization start time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of effective complete resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Young Mania Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retention in care
Endpoint domain: Mortality/survival
Primary endpoint: Attrition from PMTCT
Endpoint domain: Mortality/survival
Primary endpoint: VLDL1 and VLDL2-triglyceride secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects achieving PCV7-specific antibody concentrations of at least 0.2 mg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of subjects achieving sero-protective levels of MenC specific serum bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety of the BioFreedom stent
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of the BioFreedom stent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in minutes of moderate-vigorous physical activity (MVPA) per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relocation of ureters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Uveoscleral outflow changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Receptor Occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall safety profile of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum effect (Emax) for Drug Liking VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IKDC subjective part for functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lysholm for functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: KOOS for functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of subjects reaching ≤ 4 mm in periodontal sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Schirmer's Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of Type 2 Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % Change in Framingham 30-Year Cardiovascular Disease (CVD) Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: M50 Latency (Left Hemisphere)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: M50 Latency (Right Hemisphere)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Steady State Inter Trial Coherence (Left Hemisphere)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Steady State Inter Trial Coherence (Right Hemisphere)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GABA (Left Hemisphere)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in infiltrating CD8+ T cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adequate Control of Intravascular Hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transfusion Avoidance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of Single Word Selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accuracy of Sentence Selection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lesions detected by Pixyl.Neuro software
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Folliculogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Concentration of Fatty Acids and Their Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Verbal rating scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Waist to height ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number triggered gag reflex during the intubation of the endoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of attempts of intubation with the endoscope through the upper esophageal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Extent of salivation during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: T-lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Consumption of IV fentanyl intra-operative
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Consumption of opioid in the early postoperative
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Systolic Blood Pressure Change From Baseline to Second Stress Task Experience
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference of Pre-count and Baseline Self-reported Negative Affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: serum pharmacokinetic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Tissue Property
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adequate kidney perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in neuronal activity during a working memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neuronal activity during a stochastic learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neuronal activity during an implicit learning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in neuronal activity during an executive functioning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Body Composition at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Cardiorespiratory Fitness at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Muscle strength at 3 months. Dynamic strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (PFS) Times
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of injuries of major clinical significance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of injuries of major or minor clinical importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of moderate and severe asthma exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Rate of Force Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in asthma quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Percent of Days With Reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Number of Reflux Episodes Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean GERD-HRQL Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Illness Management Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bone Volumetric Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic elasticity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients who achieve metabolic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of hESC derived RPE cells
Endpoint domain: Adverse events/effects
Primary endpoint: Change in periodontal pocket depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bacterial load of Porphyromonas gingivalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Coronary artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage variation of Insulin-like growth factor-1 (IGF-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with somatic pathogenic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with germline pathogenic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change From Baseline in Urinary Protein/Creatinine Ratio at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Change From Baseline of Urinary Protein/Creatinine Ratio at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Glomerular Filtration Rate at Month 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ED95 of bupivacaine minimum effective volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior capsule Opacification (PCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrinsic Motivation Inventory (IMI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of local signs of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Level of social engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Prepulse inhibition of acoustic startle response (PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Quality of life (Kidscreen-27 (parents version))
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in quality of sleep (the Pittsburgh Sleep Quality Index (PSQI))
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Body Composition Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hippocampal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of symptomatic malaria (due to any Plasmodium species)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic P. falciparum malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of symptomatic P. vivax malaria
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cerebral vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of delayed cerebral ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EMG responses to peripheral nerve stimulation and motor cortex stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dispense quantity of prescribed opioids
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient falls
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Blood Pressure (Systolic and Diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fat Free Mass (FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Patient Generated Subjective Global Assessment (PG-SGA) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minimal Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medium-term acceptance of robotic tele-interaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset and duration of neural inspiratory time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tear Film Break-Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface damage as measured by fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypothalamic function response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decreased body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 30% improvement in global scores of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% improvement in joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% improvement in fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Identification of tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent OFF Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor size by CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: AUC of digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health condition assessed by self-administered questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: best corrected mesopic log contrast sensitivity function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Effort tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With TEAEs Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Time to initiation of radiation and adjuvant therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: REE changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCA changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: REE and MCA correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of AT9283
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety, tolerability, toxicity profile, and dose-limiting toxicity of AT9283
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarkers for leukocyte phenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fever Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Body Fat %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cost related to management pathways
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced time to remission from major depressive disorder
Endpoint domain: Mortality/survival
Primary endpoint: Time to Onset of Near-syncopal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Composite Endpoint of Clinical Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C absolute value and percent change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in positive body image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in post-traumatic stress symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Best corrected distance visual acuity (5 m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Distance corrected near visual acuity (40 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular Distance corrected intermediate visual acuity (80 cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of azacitidine as measured by frequency and grade of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful selective angiographies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Growth Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to the Last Quantifiable Drug Plasma Concentration (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve 0 to 72 Hours (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Top walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking cadence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of red blood cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in repetitive negative thinking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Melbourne Assessment 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Relative Difference to Reference Standard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator Global Assessment (IGA) scale for acne vulgaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Incisors' positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Severity Index (C-ISI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pittsburgh Sleep Quality Index (C-PSQI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Normalized LL-37 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Left Ventricular Mass Index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes